BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Go back to BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease| INSMED (NASDAQ: INSM) | Delayed: 120.00 -3.98 (3.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.98 | 52 Week High | $19.30 | |||
| Open | $123.89 | 52 Week Low | $9.02 | |||
| Day High | $124.11 | P/E | N/A | |||
| Day Low | $119.32 | EPS | $-1.69 | |||
| Volume | 3,445,008 | |||||
